Public Board of Directors papers 29.09.22

25/22 Key Reports

a Chief executive’s report RS drew attention to the following from his report;

Situation report – covid is still a feature of this and we were in a deescalating situation, but this is changing and there is an increasing prevalence in communities now reflected in the number of covid patients in general & acute beds, approximately 10% at this time. There are also other factors including emergency pressures and elective backlog. There is no significant impact at The Christie, although there is some increase in staff absence. A collective submission has now been made for the system plan for 2022/23. There are some significant challenges, but this has been agreed. RS confirmed that the Annual Report & Accounts has been submitted and we await the auditor’s assessment of value for money to complete our submission to be laid before parliament. Clinical academic successes were outlined including JY’s appointment to a NIHR role. RS noted that some of these clinicians are considered as emerging so are very positive. TK noted the 5Live interviews yesterday. RS noted that they were broadcasting from the Trust and it was very positive. NB noted that early diagnosis is a focus, and we are well connected with local and national media around promotion of these messages and raising awareness. GP asked about how we work with primary care around this. RS noted that Manchester Cancer work in this arena with Christie clinicians who engage through the primary care networks across GM. The numbers of referrals are back to just over what they were pre-pandemic which shows that we are getting the patients through. b Clinical leadership report NB noted that this is an update for the Board and shows the changes that have been made in clinical leadership across the organisation. This shows the fit with the clinical divisions and the leadership structures within the divisions and the development of aspirant leaders for clinical staff. Next steps are also outlined with leadership at a pathway level. CO asked what issues have been addressed through this. NB noted that we have more clinical leaders at Board with Research & Education represented. Digital clinical leadership is being prioritised as well as clinical outcomes. We are also looking to further represent allied health professionals (AHP’s). GP asked about the long-term vision and where are we furthest away from our ambition. NB responded that we need to look at our reach across the wider system as clinical leaders and influencing cancer care more. The internal clinical leadership is in a good place. JM noted the development programme and asked how this is measured. NB responded that we are looking at being more controlled around how we do this and who gets opportunities, the outreach and development of further leadership outside is being focused on. KW asked how well the current structure reflects all AHPs including pharmacists, physics, radiotherapists etc. JY responded that there is clear leadership in these

4